<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01417052</url>
  </required_header>
  <id_info>
    <org_study_id>LX3305.1-106-RA</org_study_id>
    <secondary_id>LX3305.106</secondary_id>
    <nct_id>NCT01417052</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis</brief_title>
  <official_title>A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects With Active Rheumatoid Arthritis (RA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexicon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lexicon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the safety of LX3305 in a dose escalation
      compared with placebo over 12 weeks in subjects with active rheumatoid arthritis (RA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects experiencing an adverse event (AE)</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in absolute lymphocyte counts</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at which maximum observed plasma concentration occurs</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of drug in plasma</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in global health</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>50 mg LX3305 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg LX3305 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>150 mg LX3305 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg LX3305 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>250 mg LX3305 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>300 mg LX3305 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg LX3305 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>250 mg LX3305 BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>500 mg LX3305 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mg LX3305 QD</intervention_name>
    <description>50 mg LX3305 once daily in capsule form</description>
    <arm_group_label>50 mg LX3305 QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg LX3305 QD</intervention_name>
    <description>100 mg LX3305 once daily in capsule form</description>
    <arm_group_label>100 mg LX3305 QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>150 mg LX3305 QD</intervention_name>
    <description>150 mg LX3305 once daily in capsule form</description>
    <arm_group_label>150 mg LX3305 QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200 mg LX3305 QD</intervention_name>
    <description>200 mg LX3305 once daily in capsule form</description>
    <arm_group_label>200 mg LX3305 QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>250 mg LX3305 QD</intervention_name>
    <description>250 mg LX3305 once daily in capsule form</description>
    <arm_group_label>250 mg LX3305 QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>300 mg LX3305 QD</intervention_name>
    <description>300 mg LX3305 once daily in capsule form</description>
    <arm_group_label>300 mg LX3305 QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>400 mg LX3305 QD</intervention_name>
    <description>400 mg LX3305 once daily in capsule form</description>
    <arm_group_label>400 mg LX3305 QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>250 mg LX3305 BID</intervention_name>
    <description>250 mg LX3305 twice daily in capsule form</description>
    <arm_group_label>250 mg LX3305 BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>500 mg LX3305 QD</intervention_name>
    <description>500 mg LX3305 once daily in capsule form</description>
    <arm_group_label>500 mg LX3305 QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo dosing in capsule form</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects, aged 18 to 75 years

          -  Active rheumatoid arthritis (RA), class I to III (defined by the American College of
             Rheumatology), diagnosed at least 3 months prior to Screening

          -  Minimum of 4 swollen joints (at Screening and Day 1), minimum of 4 tender joints (at
             Screening and Day 1), and serum C-reactive protein (CRP) level &gt;1.2x the upper limit
             of normal and/or elevated erythrocyte sedimentation rate (ESR)

          -  If receiving methotrexate (7.5 mg to 25 mg/week), subject must have been treated for
             at least 6 weeks prior to Screening and currently receiving a stable dose of
             methotrexate (MTX) with a stable route of administration, and have no plans to change
             MTX dose during the study

          -  Ability to give written informed consent

        Exclusion Criteria:

          -  Women who are pregnant or nursing

          -  RA diagnosis prior to 16 years of age (juvenile RA)

          -  Intra-articular and/or parenteral corticosteroids within 4 weeks of study Day 1

          -  Receipt of live vaccine within 4 weeks prior to Day 1

          -  Major surgical procedure within 8 weeks prior to Day 1

          -  Blood donation within 4 weeks prior to Day 1

          -  Any systemic inflammatory condition

          -  History of bleeding diathesis

          -  History of medically significant opportunistic infection

          -  History of drug or alcohol abuse within 3 years prior to Day 1

          -  History of cancer within 5 years prior to Day 1

          -  Presence of hepatic or biliary disease

          -  History of tuberculosis

          -  History of human immunodeficiency virus (HIV)

          -  Any clinically significant laboratory test results, in the opinion of the investigator

          -  Use of any investigational agent or participation in an investigative trial within 30
             days of Day 1

          -  Concurrent use of any biologic agent for the treatment of RA or concomitant disease
             modifying antirheumatoid drugs (other than MTX, hydroxychloroquine, leflunomide, and
             sulfasalazine - at stables doses for 8 weeks)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Freiman, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Lexicon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2011</study_first_submitted>
  <study_first_submitted_qc>August 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2011</study_first_posted>
  <last_update_submitted>August 1, 2012</last_update_submitted>
  <last_update_submitted_qc>August 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

